KSC · 069620.KS
Daewoong pharmaceutical Co.,Ltd
₩101,100-₩400 (-0.39%)
Daewoong pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 49.3% below the high.
Loading market information…
KSC · 000100.KS · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Yuhan Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Yuhan Corporation’s forward annual dividend is ₩600 per share, paid annual. The forward yield is 0.8% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Yuhan Corporation’s next earnings report is currently expected on Feb 17, 2027, with estimated earnings per share of ₩90. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Yuhan Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:28 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 |
|---|
| Jul 30, 2025 |
| ₩609+110.29% vs estimate |
| ₩578.99B-2.91% vs estimate |
| Q1 2025 | May 8, 2025 | ₩118-53.4% vs estimate | ₩491.56B-4.86% vs estimate |
|---|
| Q4 2024 | Feb 14, 2025 | -₩284-188.6% vs estimate | ₩496B-3.51% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩101,100-₩400 (-0.39%)
Daewoong pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 49.3% below the high.
₩23,000-₩150 (-0.65%)
JW Pharmaceutical Corporation’s quoted price sits in the lower half of its reported 52-week range, 41.4% below the high.
₩12,580+₩10 (+0.08%)
Ildong Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 72.08% below the high.
₩3,670-₩30 (-0.81%)
Bukwang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 62.89% below the high.
₩6,570-₩110 (-1.65%)
Hyundai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.83% below the high.
₩24,750-₩250 (-1.0%)
Daihan Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.8% below the high.
₩5,100-₩60 (-1.16%)
Dongwha Pharm.Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 32.54% below the high.
₩6,960+₩50 (+0.72%)
Ilyang Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
